In November 2025, SOE Medical Procurement of Ukraine renegotiated the managed entry agreements (MEAs) with the international pharmaceutical company Sanofi for the purchase of four innovative medicines for rare diseases that were previously purchased. According to the Health Ministry in a press release, the MEAs were concluded for a period of three years, the first deliveries are expected by the end of 2025. The MEAs were renegotiated for the purchase of such medicines as laronidase for patients